Liquidity is under significant pressure as cash reserves plummeted to $21.9 million in 2025Q3, and the OCF/NI ratio of 9.54 highlights a fundamental disconnect between accounting earnings and actual cash-depleting operations.
| Cash from Operations | -113.65M | -88.56M | -52.74M | -102.45M | -91.82M | -70.14M | -40.35M | -28.12M |
| Operating CF Margin % | - | -445.22% | -893.38% | - | - | - | - | -78108.33% |
| Operating CF Growth % | -100.31% | -67.91% | 48.52% | -11.57% | -30.91% | -73.85% | -43.48% | - |
| Net Income | -62.63M | -131.67M | -126.61M | -136.64M | -119.15M | -80.52M | -61.32M | -35.8M |
| Depreciation & Amortization | 4.85M | 4.93M | 5.26M | 5.13M | 4.53M | 3.43M | 1.86M | 347K |
| Stock-Based Compensation | 8.84M | 14.61M | 24.34M | 24.45M | 17.86M | 8.41M | 4.21M | 3.49M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -22.37M | 54.99M | -9.27M | 3.56M | 766K | 249K | -327K | -834K |
| Working Capital Changes | -42.35M | -31.43M | 53.54M | 1.05M | 4.17M | -1.71M | 15.23M | 4.68M |
| Change in Receivables | 1.82M | -1.22M | -3.56M | -395K | 0 | 448K | 840K | -1.29M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -448K | 0 | 0 |
| Change in Payables | 418K | -386K | 1.09M | -1.39M | 1.76M | -1.44M | 761K | 223K |
| Cash from Investing | 113.72M | 94.53M | -9.7M | -192.51M | 193.05M | -205.2M | 47.98M | -69.76M |
| Capital Expenditures | -1.08M | -2.4M | -7.4M | -8.8M | -5.96M | -5.52M | -19.99M | -3.02M |
| CapEx % of Revenue | 7.09% | 12.07% | 125.29% | - | - | - | - | 8391.67% |
| Acquisitions | 492K | 196K | 0 | 0 | 105K | 199.68M | 80K | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 30K | 0 | 0 | 0 | 105K | -199.68M | 0 | -66.74M |
| Cash from Financing | 215K | 250K | 35.82M | 12.99M | 214.67M | 323.1M | 78K | 100.19M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 232K | 436K | 1000K | 1000K | 1000K | 1000K | 100K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -17K | -186K | -183K | -581K | 2.79M | 341K | -22K | 0 |
| Net Change in Cash | 283K | 6.22M | -26.63M | -281.97M | 315.9M | 47.76M | 7.77M | 2.31M |
| Free Cash Flow | -114.73M | -90.96M | -60.14M | -111.25M | -97.78M | -75.66M | -60.33M | -31.14M |
| FCF Margin % | -751.38% | -457.29% | -1018.67% | - | - | - | - | -86500% |
| FCF Growth % | -9.94% | -51.25% | 45.94% | -13.78% | -29.23% | -25.41% | -93.74% | - |
| FCF per Share | -17.03 | -13.65 | -9.33 | -19.14 | -17.37 | -27.76 | -13.06 | -15.81 |
| FCF Conversion (FCF/Net Income) | 1.83x | 0.67x | 0.42x | 0.75x | 0.77x | 0.87x | 0.67x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liquidity and clinical dependency
As reported in recent financial statements, the company's operating cash flow consistently trails net income, with the 2025Q3 OCF/NI ratio of 9.54 highlighting a significant divergence that suggests accounting-based revenue recognition is failing to provide a reliable proxy for the underlying cash-depleting reality of the business.
The wide gap between net income and operating cash flow indicates that non-cash items and working capital fluctuations are heavily distorting the perceived financial health. Investors should monitor this persistent negative cash conversion, as it implies that the company's reported earnings are not translating into the liquidity required to sustain its R&D-heavy operating model.
Based on quarterly data, the company's free cash flow trajectory remains deeply negative, with a 2025Q3 FCF margin of -33.0% reflecting a structural inability to generate internal funding, a trend that underscores the company's ongoing reliance on external capital to support its clinical development pipeline.
The consistent negative FCF trajectory suggests that the business model is currently incapable of self-funding its research initiatives. This trend warrants further investigation into how long the current cash reserves can support such high burn rates before the company is forced to seek dilutive financing.
According to recent SEC filings, the company experienced a significant working capital outflow of $26.4 million in 2025Q3, a sharp reversal that highlights the inherent volatility in managing cash flows tied to project-based collaboration milestones rather than predictable, recurring operational cycles.
The erratic nature of working capital changes suggests that the company's liquidity is highly sensitive to the timing of milestone payments and contract-related cash inflows. This volatility complicates cash flow forecasting and may indicate that the company lacks the operational maturity to stabilize its short-term liquidity needs.
As disclosed in financial filings, the company consistently utilizes stock-based compensation, with $2.0 million recorded in 2025Q3, which serves to artificially inflate the cash flow statement by masking the true economic cost of talent acquisition required to maintain its proprietary genetic medicine platform.
While stock-based compensation is a non-cash expense, its consistent use suggests that the company is effectively using equity to subsidize its operating cash burn. Analysts should adjust for these items to understand the true cash-based cost of operations, as the current reporting may understate the actual financial burden of the company's human capital requirements.
Quick answers to the most common questions about buying GBIO stock.
Generation Bio Co. (GBIO) generated $-88.6M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Generation Bio Co. (GBIO) reported negative free cash flow of $91.0M in 2024, indicating capital requirements exceeded cash from operations.
Generation Bio Co. (GBIO) spent $2.4M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.